| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| DARZALEX | $2.88B | $3.02B | $3.08B | $3.24B | $3.54B | $3.67B | $3.90B | $3.96B |
| Other | $305.00M | $292.00M | $281.00M | $2.84B | $309.00M | $264.00M | $249.00M | $2.90B |
| Tremfya | $906.00M | $1.01B | $949.00M | $956.00M | $1.19B | $1.42B | $1.59B | $1.61B |
| GENERAL | $1.35B | $1.33B | $1.36B | $1.32B | $1.39B | $1.38B | $1.47B | $1.39B |
| ADVANCED | $1.14B | $1.11B | $1.15B | $1.07B | $1.16B | $1.17B | $1.18B | $1.12B |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | $1.05B | $1.05B | $1.06B | $903.00M | $992.00M | $929.00M | $986.00M | $1.04B |
| CONTACT LENSES / OTHER | $918.00M | $968.00M | $937.00M | $919.00M | $965.00M | $1.02B | $1.01B | $969.00M |
| ERLEADA | $736.00M | $790.00M | $784.00M | $771.00M | $908.00M | $936.00M | $959.00M | $949.00M |
| TRAUMA | $759.00M | $761.00M | $764.00M | $772.00M | $768.00M | $793.00M | $813.00M | $833.00M |
| SPINE & OTHER | $743.00M | $696.00M | — | $671.00M | $727.00M | $698.00M | — | $694.00M |
| IMBRUVICA | $770.00M | $753.00M | $731.00M | $709.00M | $735.00M | $695.00M | $684.00M | $660.00M |
| STELARA | $2.89B | $2.68B | $2.35B | $1.63B | $1.65B | $1.57B | $1.23B | $656.00M |
| SIMPONI / SIMPONI ARIA | $537.00M | $516.00M | $583.00M | $659.00M | $690.00M | $687.00M | $632.00M | $647.00M |
| XARELTO | $587.00M | $592.00M | $676.00M | $690.00M | $621.00M | $635.00M | $687.00M | $642.00M |
| OPSUMIT/OPSYNVI | — | — | — | $522.00M | $582.00M | $578.00M | — | $606.00M |
| CARVYKTI | $186.00M | $286.00M | $334.00M | $369.00M | $439.00M | $524.00M | $555.00M | $597.00M |
| UPTRAVI | $426.00M | $458.00M | $465.00M | $451.00M | $476.00M | $484.00M | $491.00M | $483.00M |
| SPRAVATO | $271.00M | $284.00M | $297.00M | $320.00M | $414.00M | $459.00M | $503.00M | $468.00M |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | $438.00M | $449.00M | $407.00M | $403.00M | $396.00M | $397.00M | $383.00M | $443.00M |
| HIPS | $417.00M | $381.00M | $418.00M | $409.00M | $421.00M | $405.00M | $439.00M | $436.00M |
| Remicade | $393.00M | $419.00M | $359.00M | $467.00M | $455.00M | $476.00M | $370.00M | $422.00M |
| KNEES | $394.00M | $352.00M | $398.00M | $389.00M | $389.00M | $377.00M | $432.00M | $420.00M |
| EDURANT/rilpivirine | $297.00M | $330.00M | $322.00M | $358.00M | $360.00M | $385.00M | $383.00M | $409.00M |
| SURGICAL | $367.00M | $333.00M | $365.00M | $361.00M | $403.00M | $383.00M | $411.00M | $396.00M |
| CAPLYTA | — | — | — | — | $211.00M | $240.00M | $249.00M | $270.00M |
| OTHER NEUROSCIENCE | $294.00M | $281.00M | $255.00M | $277.00M | $270.00M | $256.00M | $245.00M | $262.00M |
| RYBREVANT + LAZCLUZE | — | — | — | $141.00M | $179.00M | $198.00M | $216.00M | $257.00M |
| Tecvayli | $135.00M | $135.00M | $146.00M | $151.00M | $166.00M | $177.00M | $176.00M | $202.00M |
| Other Oncology | $83.00M | $86.00M | $75.00M | $214.00M | $93.00M | $94.00M | $100.00M | $192.00M |
| TALVEY | — | — | — | $86.00M | $106.00M | $122.00M | $149.00M | $152.00M |
| CONCERTA/Methylphenidate | $163.00M | $142.00M | $159.00M | $148.00M | $164.00M | $140.00M | $132.00M | $136.00M |
| OTHER IMMUNOLOGY | $2.00M | $1.00M | $0.00 | $1.00M | $8.00M | $12.00M | $40.00M | $46.00M |
| OTHER INFECTIOUS DISEASES | $233.00M | $56.00M | $45.00M | $41.00M | $47.00M | $47.00M | $40.00M | $37.00M |
| ELECTROPHYSIOLOGY | $1.32B | $1.32B | $1.32B | $1.41B | $1.41B | $1.41B | $1.41B | — |
| other cardiovascular | — | — | — | $99.25M | $99.25M | $99.25M | $99.25M | — |
| SPINE,SPORTS & OTHER | $731.50M | $731.50M | $731.50M | $713.00M | $713.00M | $713.00M | $713.00M | — |
| Total | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B |
ELECTROPHYSIOLOGY, Abiomed, other cardiovascular, SPINE,SPORTS & OTHER are derived from annual filings.